Clinical studies have demonstrated that GLP-1 receptor agonists can reduce various inflammatory biomarkers , including: C-reactive protein (CRP) : A general marker of systemic inflammation Interleukin-6 (IL-6) : A pro-inflammatory cytokine Tumour necrosis factor-alpha (TNF-) : Another key inflammatory mediator Plasminogen activator inhibitor-1 (PAI-1) : Associated with cardiovascular inflammation The magnitude of these effects varies between studies and may depend on baseline inflammatory status, degree of weight loss achieved, and individual patient characteristics
The cost associated with including these GLP-1s on the health plan to reduce obesity actually did the opposite: it led to an increased claims liability for the employer and insurance companies
Methylene blue malaria treatment was one of the first synthetic antimalarial drugs, targeting the Plasmodium parasite
The emerging gut-ovary-brain axis framework that ovarian dysfunction in PCOS is partly mediated by gut microbiome imbalance and altered neuroendocrine signaling is generating serious research attention
Neuregulin-4 (Nrg4), an adipokine, has protective effects against metabolic disorders and insulin resistance
Understanding Brain Fog on Ozempic What is Brain Fog
